ALK is an inclusion eligibility criterion in 6 clinical trials for transformed non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain ALK status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 28 clinical trials for transformed non-hodgkin lymphoma, of which 25 are open and 3 are closed. Of the trials that contain BCL2 status and transformed non-hodgkin lymphoma as inclusion criteria, 7 are phase 1 (5 open), 8 are phase 1/phase 2 (7 open), 8 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open) [3].

BCL6 is an inclusion eligibility criterion in 26 clinical trials for transformed non-hodgkin lymphoma, of which 24 are open and 2 are closed. Of the trials that contain BCL6 status and transformed non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (5 open), 8 are phase 1/phase 2 (7 open), 8 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [3].

CCND1 is an inclusion eligibility criterion in 3 clinical trials for transformed non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and transformed non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [3].

CD274 is an inclusion eligibility criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IGH is an inclusion eligibility criterion in 2 clinical trials for transformed non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 29 clinical trials for transformed non-hodgkin lymphoma, of which 26 are open and 3 are closed. Of the trials that contain MYC status and transformed non-hodgkin lymphoma as inclusion criteria, 8 are phase 1 (6 open), 8 are phase 1/phase 2 (7 open), 8 are phase 2 (8 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open) [3].